The Diary Of A CEO

The Peptide Expert: Big Pharma Are Hiding This Powerful Peptide From You! - Dr. Alex Tatem

with Dr. Alex Tatem
20 Apr 2026 17 min read 1h 47m
TL;DR

Peptides are highly targeted, amino-acid-based medications that can treat everything from injury repair to weight loss to fertility, but were banned by the FDA in 2023 despite years of safe clinical use—likely because Big Pharma can't patent naturally-occurring compounds and saw them as a threat to profit. The FDA is now reconsidering legalization of seven peptides in July 2026, signaling a major shift in how medicine could be delivered.

Key Moments
Dr. Alex Tatem
“110% because the question isn't what can peptides do, it's what can't they do.”
Responding to whether Big Pharma deliberately suppressed peptides because they can't be patented and are powerful
▶ 0:43
Dr. Alex Tatem
“Peptides are derived from little pieces of amino acids, which think of them as the Legos that make up the human body, the Legos that make up proteins. These are fragments of proteins that are designed to specifically target certain receptors and affect cells in a very targeted fashion.”
Explaining the fundamental mechanism of how peptides work during the initial education segment
▶ 3:49
Dr. Alex Tatem
“And then in 2023, the FDA at that time switched all of those peptides, 19 of them that were popular, to category two, and then they were banned. Overnight, we got notifications in our email inboxes from our compounding pharmacy partners saying, 'Hey, we can't make this anymore. We're sorry.'”
Describing the sudden 2023 FDA ban that ended a decade of legal peptide access to patients
▶ 14:05
Dr. Alex Tatem
“The truth is is that they are these large machines that are designed to prioritize profit over everything.”
Explaining why pharmaceutical companies might have influenced the peptide ban despite safety data
▶ 19:05
Dr. Alex Tatem
“So, I just saw a patient last last week who increased his sperm count 10 times over and is now in a normal range because he's lost 100 lb due to using tirzepatide, exercising, and improving his diet. And he has totally changed his life.”
Sharing a real-world clinical outcome showing how peptide-driven weight loss solved infertility as a downstream effect
▶ 22:31
About Dr. Alex Tatem
›
Dr. Alex Tatem is a urology expert and peptide researcher who has been at the forefront of understanding how peptides can revolutionize treatment outcomes for injury recovery, weight loss, fertility, and longevity. He spent years prescribing peptides to patients through compounding pharmacies before they were banned by the FDA in 2023, and has become a vocal advocate for their legalization and accessibility. His work challenges conventional pharmaceutical business models and explores why compounds with proven clinical efficacy have been restricted from public use.
Takeaways
1
Peptides are protein fragments targeting specific receptors Unlike small-molecule drugs that have broad effects throughout the body, peptides function as highly specific 'keys' that unlock targeted cellular receptors. This precision means fewer side effects and better therapeutic outcomes—but also means they're harder to patent and profit from, which is why pharmaceutical companies have less incentive to develop them commercially.
2
FDA ban in 2023 was likely profit-driven, not safety-driven Despite years of clinical use with no reported adverse events, the FDA reclassified peptides from legal to banned in 2023, citing insufficient data—a reversal that benefits pharmaceutical companies far more than patient safety. The timing follows the Myriad case preventing patent protection on natural compounds, making peptides a financial threat to Big Pharma's business model.
3
FDA reconsidering seven peptides for legalization in July 2026 The FDA announced it will review seven peptides for potential relegal status, including BPC-157 (injury repair), TB-500 (tissue healing), and MOTS-c (exercise performance). This signals pressure from the incoming administration and growing public demand, potentially opening a major market for compounding pharmacies and forcing pharmaceutical companies to develop their own peptide products through AI-assisted discovery.